We recently published results of targeted sequencing applied to 928 unselected cases of diffuse large B-cell lymphoma (DLBCL) listed in the Haematological Malignancy Research Network (HMRN) registry.1 Clustering allowed us to resolve five genomic subtypes. (D) IPI-adjusted hazard ratios for classified patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisolone) are shown relative to the unclassified "Other" patients. Hazard ratios (HR) were calculated using a Cox model based on either overall survival or progression free survival, as indicated. gl In summary, we conclude that mutation-only data from targeted sequencing allows a confident LymphGen classification in just over 50% of patients. Unadjusted and IPI-adjusted hazard ratios for R-CHOP-treated patients classified by either Modified HMRN or the LymphGen classifier relative to the unclassified "Other" patients. [Extracted from the article]